In brief
The FDA has formally warned telehealth companies, including Hims & Hers, for promoting unapproved versions of prescription medications, specifically targeting claims of equivalence to FDA-approved drugs. This action is part of a broader initiative aiming to ensure that pharmaceutical advertisements are truthful and not misleading. The letters demand the removal of deceptive marketing practices that mislead consumers about drug safety and efficacy.
WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the Trump administration’s crackdown on pharmaceutical advertising.
The Food and Drug Administration on Tuesday posted more than 100 letters to various drug and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered around lower-cost versions of blockbuster obesity injections.
The FDA warned the company to remove false and misleading promotional statements from its website, including language claiming that its customized products contain the same active ingredient as FDA-approved drugs Wegovy and Ozempic. The formulations cited by regulators are produced by specialty compounding pharmacies and aren’t reviewed by the FDA.
“Your claims imply that your products are the same as an FDA-approved product when they are not,” states the warning letter, dated Sept. 9.
It’s the first FDA attempt to directly police online platforms like Hims, which have long argued they’re not subject to drug advertising rules.
A memo signed by President Donald Trump last week directed Health Secretary Robert F. Kennedy Jr. and the FDA to ensure that pharmaceutical ads on TV, social media and other websites are “truthful and non-misleading.” As part of the initiative, the FDA promised to send 100 letters to companies with deceptive ads.
The new FDA letters each contain “cease and desist” language. That’s a different approach for the agency, which typically drafts its letters in highly bureaucratic language citing specific FDA regulations. Hims has been under scrutiny from Washington for months.
Earlier this year, a Super Bowl ad from the company touted the benefits of its weight-loss medications but didn’t list any of their side effects or potential harms. FDA rules require advertisements to present a balanced picture of drug risks and benefits.
Researchers and consumer advocates have long complained that the upbeat TV images of patients enjoying life often overshadow discussions of side effects. The American Medical Association has supported a ban on such advertising, citing its role in inflating demand for expensive drugs.
